CM
AUPH icon

Capula Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Capula Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35,670
Closed -$320K – 684
2024
Q4 		$320K Buy
+35,670
New +$291K ﹤0.01% 226

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capula Management's AUPH Position: Q1 2025 in Review

Capula Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 35,670 shares — an estimated $320K sold.

Capula Management first reported a position in AUPH in Q4 2024 and held it in 1 quarter. The position peaked at $320K in Q4 2024. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • Capula Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Capula Management sold 35,670 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $320K.
  • Capula Management first reported a position in Aurinia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Capula Management's Aurinia Pharmaceuticals position peaked at $320K in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Capula Management's 13F filing for Q1 2025, filed 14 May 2025.